A Case Series of Bacillary Layer Detachment (BALAD) in Neovascular Age-Related Macular Degeneration (nAMD): A Novel Optical Coherence Tomography (OCT) Biomarker

新生血管性年龄相关性黄斑变性(nAMD)中杆状层脱离(BALAD)的病例系列研究:一种新型光学相干断层扫描(OCT)生物标志物

阅读:1

Abstract

Bacillary layer detachment (BALAD) is a newly recognized optical coherence tomography (OCT) finding, defined as a split at the photoreceptor inner segment (myoid zone) resulting in a dome-shaped intraretinal fluid cavity. BALAD has been reported in various chorioretinal diseases and may serve as a novel structural OCT biomarker of severe exudation. We present a case series of BALAD in neovascular age-related macular degeneration (nAMD) to characterize its multimodal imaging features and discuss its diagnostic and prognostic significance. Three patients with active nAMD exhibited BALAD on spectral-domain OCT. In each instance, OCT cross-sections showed a sharply demarcated hyporeflective intraretinal cavity beneath an intact external limiting membrane (ELM) and above the ellipsoid zone (EZ). OCT angiography (OCTA) revealed an underlying high-flow choroidal neovascular network corresponding to the BALAD in all cases. All three patients initially had significant visual impairment. Two patients were treated with serial intravitreal anti-vascular endothelial growth factor (VEGF) injections, resulting in rapid resolution of the BALAD cavity, reabsorption of subretinal and intraretinal fluid, and marked improvement in best-corrected visual acuity (e.g., from 20/400 to 20/40). The third patient, who declined treatment, developed persistent BALAD with progressive subfoveal fibrosis and no visual recovery. BALAD in nAMD indicates an aggressive disease phenotype with intense outer retinal fluid accumulation and photoreceptor layer schisis. Prompt anti-VEGF therapy was associated with anatomical recovery and vision improvement in the treated cases. Recognizing BALAD on OCT and OCTA is clinically important, as it differentiates intraretinal from subretinal pathology and underscores the need for early, aggressive treatment to mitigate irreversible retinal damage in nAMD.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。